logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Incyte Corporation Skyrockets on Promising Trial for Jakafi

  +Follow August 21, 2013 9:20AM
Share:
Tickers Mentioned:

Pharmaceutical company Incyte Corporation (INCY) released very positive news on Aug. 21, revealing that their pancreatic cancer treatment drug ruxolitinib, marketed under the trade name Jakafi, had performed very well in Phase II trials, and that the drug could now move on to Phase III.

Incyte Executive Vice President Richard S. Levy pointed out that sufferers from advanced pancreatic cancer currently have very few options. If approved, the orally-administered drug would be one of the first on the market that exists as "an attractive treatment option" for sufferers of pancreatic cancer.

If approved by the FDA, this would be a major breakthrough. Metastatic pancreatic cancer has the lowest survival rate of any form of cancer. Currently, less than one percent of people afflicted survive more than five years.

Jakafi's ability to increase lifespan for sufferers looks very promising. In the Phase II trials, the six month survival rate for patients (when coupled with chemotherapy treatment) for Jakafi was 42 percent, compared to 11 percent for patients on a placebo.

Jakafi was first approved by the Food and Drug Administration in 2011 to treat a bone marrow disease. After its success in that arena, the company specualted that the drug might effectively treat other types of cancer as well. Now, the drug is fast aproaching approval to treat pancreatic cancer as well. Though it is currently the only drug the company has gotten passed by the USFDA. Jakafi seems to be fulfilling early analyst speculation that it could be a billion dollar blockbuster drug for the Delaware-based drug maker.

Incyte earned $54.1 million from sales of Jakafi in the second quarter of 2013, and expects to earn between $220 and $230 million total this year.

Incyte rocketed on the news, and went up 29.19 percent to hit $34.88 a share. They’re up 58.82 percent on the year.

(image courtesy of Wikimedia commons)

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com and Connect With Your Favorite Financial Experts FOR FREE! Members of Equities.com gain access to our leading financial news and content, active social investment community, proprietary research tools including the 2014 Small-Cap Stars, E.V.A. reports and more.

Results for INCY
Jacob Plieth
21 Oct 14 03:23:25
SanRx $NLNK $INCY RT @DatamonitorMark: They’ve been following this line of thinking for a few years: http://t.co/fVgfW0w0js
Jacob Plieth
21 Oct 14 03:04:17
How about that? SanRx says it's selling an IDO inhibitor as a dietary supplement http://t.co/lfi3tiNyOQ $NLNK $INCY $RHHBY
12Stocks.com
21 Oct 14 03:03:32
Weekly MidCap #Stocks Trend $SHLD $TMHC $NSM $ARIA $OCN $LII $LEN $DPZ $DHI $PHM $FEYE $THRX $INCY $ADS $ALK @ http://t.co/tf79gD96D3
Dr. Paul DeSantis
20 Oct 14 23:25:15
$INCY Jefferies: $NLNK $RHHBY IDO-1 deal Validates INCY's IDO-1 program already in development, data at ASCO 2015 with $MRK Keytruda
Luke Lee
20 Oct 14 22:30:43
RT @RNA_Biotech: 9 takeover targets: $ACHN $ARIA $BMRN $INCY $ISIS $JAZZ $MDVN $PBYI $SLXP http://t.co/eFtDGvHG8T
Vincent
20 Oct 14 13:23:39
wasn't able to share some of my options trades from today: $INCY $ENTA $ISIS $RCPT etc.. http://t.co/DHOOt4GlE1
NASDAQ
20 Oct 14 13:16:45
$INCY - Statement of Changes in Beneficial Ownership (4) http://t.co/8uqhWojFkn
$Stocknewsalerts
20 Oct 14 13:15:44
$INCY ALERT: New Incyte Corporation SEC Filing From our Stock News Alerts App
Tonsil Stone Removal
20 Oct 14 07:18:39
RT @JacobEPVantage: UBS sees an optimistic read-across to $INCY of the $RHHBY $NLNK IDO deal. http://t.co/P7VanZby4B
Jacob Plieth
20 Oct 14 07:09:21
UBS sees an optimistic read-across to $INCY of the $RHHBY $NLNK IDO deal. http://t.co/P7VanZby4B
zach
20 Oct 14 06:37:19
curious how $INCY would react if they got the roche deal instead of $NLNK
crhz1978
20 Oct 14 04:56:45
RT @RNA_Biotech: 9 takeover targets: $ACHN $ARIA $BMRN $INCY $ISIS $JAZZ $MDVN $PBYI $SLXP http://t.co/eFtDGvHG8T
biotech 2050
20 Oct 14 04:51:52
RT @JacobEPVantage: Interesting to see $RHHBY making a big $150m bet on $NLNK, versus $MRK $AZN more cautious non-exclusive approach with $…
Jacob Plieth
20 Oct 14 04:50:01
...and $RHHBY's own non-exclusive deal with $INCY, of course. $NLNK
Brad Loncar
20 Oct 14 04:48:50
RT @JacobEPVantage: Interesting to see $RHHBY making a big $150m bet on $NLNK, versus $MRK $AZN more cautious non-exclusive approach with $…
Jacob Plieth
20 Oct 14 04:47:27
Interesting to see $RHHBY making a big $150m bet on $NLNK, versus $MRK $AZN more cautious non-exclusive approach with $INCY
Hey Guy
20 Oct 14 04:45:25
RT @MTSLNews: $INCY $NLNK Impressive Genentech partnership emphasizes the potential value of IDO, which INCY is the bonafide leader in
BioInvest
20 Oct 14 04:41:56
$INCY $NLNK Impressive Genentech partnership emphasizes the potential value of IDO, which INCY is the bonafide leader in
Dan Forman
20 Oct 14 04:06:37
RT @RNA_Biotech: 9 takeover targets: $ACHN $ARIA $BMRN $INCY $ISIS $JAZZ $MDVN $PBYI $SLXP http://t.co/eFtDGvHG8T
NASDAQ
20 Oct 14 03:07:19
$INCY - Current Report Filing (8-k) http://t.co/5082avGNoG
$Stocknewsalerts
20 Oct 14 03:07:00
$INCY ALERT: New Incyte Corporation SEC Filing From our Stock News Alerts App
12Stocks.com
20 Oct 14 03:03:37
Weekly MidCap #Stocks Trend $NMBL $I $TXT $ADS $DHI $INCY $LEN $CLGX $MJN $TAHO $FCNCA $DF $SNA $CCK $DV @ http://t.co/tf79gD96D3
Sacha Pouget
20 Oct 14 02:28:36
RT @RNA_Biotech: 9 takeover targets: $ACHN $ARIA $BMRN $INCY $ISIS $JAZZ $MDVN $PBYI $SLXP http://t.co/eFtDGvHG8T
Biotech Beat
20 Oct 14 00:50:43
RT @RNA_Biotech: 9 takeover targets: $ACHN $ARIA $BMRN $INCY $ISIS $JAZZ $MDVN $PBYI $SLXP http://t.co/eFtDGvHG8T
V.S. Schulz
20 Oct 14 00:10:44
RT @RNA_Biotech: 9 takeover targets: $ACHN $ARIA $BMRN $INCY $ISIS $JAZZ $MDVN $PBYI $SLXP http://t.co/eFtDGvHG8T
RNA_Biotech
20 Oct 14 00:09:01
9 takeover targets: $ACHN $ARIA $BMRN $INCY $ISIS $JAZZ $MDVN $PBYI $SLXP http://t.co/eFtDGvHG8T
biotech 2050
19 Oct 14 23:06:40
NOMURA Target Price $GILD $141 $CELG $128 $BIIB $424 $AMGN $142 $ALXN $224 $INCY $90 $PCYC $158 $BMRN $85 40%+ upside potential $CELG $GILD
dougheuring
19 Oct 14 15:04:44
$incy Incyte (INCY; Buy; $90 TP): Expect Inflection in Jakafi Sales With 4Q PV Approval http://t.co/R81G2mgeIv
TickerChirp
19 Oct 14 14:39:03
Popular Tweets for $INCY (INCYTE CORP symbol incy) on 10/19/2014 http://t.co/WghVvHN5MX
12Stocks.com
18 Oct 14 03:16:49
Weekly MidCap #Stocks Trend $NMBL $I $TXT $ADS $DHI $INCY $LEN $CLGX $MJN $TAHO $FCNCA $DF $SNA $CCK $DV @ http://t.co/tf79gD96D3
4-traders.com
17 Oct 14 22:20:02
Incyte : Gets Payment Related to Reimbursement of Jakavi (ruxolitinib) http://t.co/rnbbBAJGzX $INCY $NOVN
MAISA
17 Oct 14 12:35:48
$INCY Names Former Celgene CFO David Gryska To CFO Post -- Shares Down Nearly -1%
SH
17 Oct 14 10:59:29
$INCY Unusual Volume INCY - 5x adv: 3733 contracts vs 680 adv, 97% calls, 11% of OI [$50.20 -1.30 Ref, IV=48.8% +2.6]
MarketCurrents
17 Oct 14 07:24:21
New finance chief at Incyte http://t.co/KYMeYO50QA $INCY
Briefing.com
17 Oct 14 07:04:07
$INCY: Incyte appoints David Gryska as EVP and CFO http://t.co/Xtal4OxYGu
Stock Moo
17 Oct 14 05:51:30
$incy: Incyte Appoints David Gryska as Executive Vice President and Chief Financial Officer http://t.co/C6Z1WMeBZU
Stock Moo
17 Oct 14 05:51:21
$incy: Incyte Appoints David Gryska as Executive Vice President and Chief Financial Officer http://t.co/O1LUr1l16F
Javid Shaik
17 Oct 14 05:05:09
#Stocks breaking above the 50 or 200 #MovingAverage. $AYI $DATA $GXP $INCY $MYL $PM $SKT $UPL $WEN
The Dynamic Trader
17 Oct 14 05:05:09
#Stocks breaking above the 50 or 200 #MovingAverage. $AYI $DATA $GXP $INCY $MYL $PM $SKT $UPL $WEN
4-traders.com
17 Oct 14 05:05:07
Incyte : Appoints David Gryska as Executive Vice President and Chief Financial Officer http://t.co/C3WHLzV9tf $INCY
$Stocknewsalerts
17 Oct 14 05:02:59
$INCY Incyte Appoints David Gryska as Executive Vice President and Chief Financial Officer From our Stock News Alerts App
NASDAQ
17 Oct 14 05:01:19
$INCY - Incyte Appoints David Gryska as Executive Vice President and Chief Financial Officer http://t.co/pJxM71ksPn
Shysterjd
17 Oct 14 05:00:57
RT @zbiotech: $INCY CFO leaving to pursue other opps
zach
17 Oct 14 05:00:45
$INCY CFO leaving to pursue other opps
BV Healthcare
17 Oct 14 05:00:36
$INCY Incyte Appoints David Gryska as Executive Vice President and Chief Financial Officer.. http://t.co/8xhJ475OPj
Anne Chapman
17 Oct 14 04:45:07
#Stocks breaking above the 50 or 200 #MovingAverage. $AYI $DATA $GXP $INCY $MYL $PM $SKT $UPL $WEN
12Stocks.com
17 Oct 14 03:03:26
Weekly MidCap #Stocks Trend $SD $UPL $THRX $NMBL $RRC $INCY $DF $GRMN $PDM $FCNCA $NNN $ATO $O $TAHO $RAX @ http://t.co/tf79gD96D3
12Stocks.com
17 Oct 14 03:03:07
Weekly MidCap #Stocks Performance $CLF $SD $UPL $SHLD $THRX $BTU $AR $DPZ $DO $VEEV $NMBL $RRC $CHK $INCY more@ http://t.co/tf79gD96D3
j l
17 Oct 14 00:33:52
@AndyBiotech @jq1234t @JasonCRG Probably best to see if recruitment does start before end of this month.Note 2mg used for RI pats $LLY $INCY
12Stocks.com
16 Oct 14 16:03:18
MidCap #Stocks Trend $THRX $INCY $RRC $ITC $NMBL $UPL $PDM $SLGN $RGLD $GRMN $PCL $TAHO $SD $PLD $HTA $UGI $O @ http://t.co/tf79gD96D3
				
				
  +Follow August 21, 2013 9:20AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.